Comparison of hysteroscopic and hysterectomy findings to assess the diagnostic accuracy of office hysteroscopy in tamoxifen-treated patients with breast cancer

Journal of the American Association of Gynecologic Laparoscopists

Volumn 10, Issue 3, 2003, Pages 392-395

  Ceci, Oronzo ^a   Bettocchi, Stefano ^a   Nappi, Luigi ^a   Di Venere, Raffaella ^a   Pansini, Maddalena Valeria ^a   Di Fazio, Francesco ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ENDOMETRIAL DISEASE; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; HUMAN; HYSTERECTOMY; HYSTEROSCOPY; INTERMETHOD COMPARISON; POLYP; SCREENING; TRANSVAGINAL ECHOGRAPHY;

EID: 0041334205     PISSN: 10743804     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-3804(05)60270-8     Document Type: Article

References (26)

1. van Leeuwen FE, Benraadt J, Coebergh JW, et al: Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343:448-452, 1994
2. Althuis MD, Sexton M, Langerberger P, et al: Surveillance for uterine abnormalities in tamoxifen-treated breast carcinoma survivors: A community based study. Cancer 89:800-810, 2000
3. Love CD, Muir BB, Scrimgeour JB, et al: Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening. J Clin Oncol 17:2050-2054, 1999
4. McGonigle KF, Shaw SL, Vasilev SA, et al: Abnormalities detected on transvaginal ultrasonography in tamoxifen-treated postmenopausal breast cancer patients may represent endometrial cystic atrophy. Am J Obstet Gynecol 178:1145-1150, 1998
5. Kedar RP, Bourne TH, Powles TJ, et al: Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 343:1318-1321, 1994
6. Neven P, Vernaeve H: Guidelines for monitoring patients taking tamoxifen treatment. Drug Saf 22:1-11, 2000
7. Suh-Bergman EJ, Goodman A: Surveillance for endometrial cancer in women receiving tamoxifen. Ann Intern Med 131:127-135 1999
8. Barakat RR, Gilewski TA, Almadrones L, et al: Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: A prospective study using office endometrial biopsy. J Clin Oncol 18:3459-3463, 2000
9. Piccolboni G, Arlacchi E, Cattani R, et al: Diagnostic value of hysteroscopy: Correlation with histological findings after dilatation and curettage and hysterectomy. Acta Eur Fertil 22:233-234, 1991
10. Cohen I, Azaria R, Bernheim J, et al: Comparison of endometrial pathologies collected by hysteroscopy and hysterectomy in postmenopausal breast cancer tamoxifen-treated patients. Eur J Gynecol Oncol 21:418-422, 2000
11. Selvaggi L, Bettocchi S, Porreca M, et al: A vaginoscopical approach to hysteroscopy. J Am Assoc Gynecol Laparosc 2:S76, 1995
12. Loffer FD: Hysteroscopy with selective endometrial sampling compared with D&C for abnormal uterine bleeding: The value of negative hysteroscopic view. Obstet Gynecol 73:16-20, 1989
13. Silva EG, Tornos CS, Follen-Mitchell M: Malignant neoplasms of the uterine corpus in patients treated for breast cancer: The effects of tamoxifen. Int J Gynecol Pathol 13:248-258, 1994
14. Touraine P, Driguez P, Cartier I, et al: Lack of induction of endometrial hyperplasia with tamoxifen. Lancet 345:254-255, 1995
15. Mencaglia L, Valle RF, Perino A, et al: Endometrial carcinoma and its precursors: Early detection and treatment. Int J Gynaecol Obstet 31:107-116, 1990
16. Ceci O, Bettocchi S, Pellegrino AR, et al: Diagnostic accuracy of office hysteroscopy: Comparison between hysteroscopic and hysterectomy findings. Fertil Steril 78:628-631, 2002
17. Cohen I, Tepper R, Rosen DJD, et al: Continuous tamoxifen treatment in asymptomatic, postmenopausal breast cancer patients does not cause aggravation of endometrial pathologies. Gynecol Oncol 55:138-143, 1994
18. Katase K, Sugiyama Y, Hasumi K, et al: The incidence of subsequent endometrial carcinoma with tamoxifen use in patients with primary breast carcinoma. Cancer 82:1698-1703, 1998
19. Lahti E, Blanco G, Kaupilla A, et al: Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 81:660-664, 1993
20. Cohen I, Beyth Y, Tepper R: The role of ultrasound in the detection of endometrial pathologies in asymptomatic postmenopausal breast cancer patients with tamoxifen treatment. Obstet Gynecol Surv 53:429-438, 1998
21. Committee on Gynecologic Practice, American College of Obstetricians and Gynecologists: Tamoxifen and endometrial cancer. Int J Gynaecol Obstet 53:197-199, 1996
22. Berliere M, Charles A, Galant C, et al: Uterine side effects of tamoxifen: A need for systematic pretreatment screening. Obstet Gynecol 91:40-44, 1998
23. Dijkhuizen FPHLJ, Brolmann HAM, Oddens BJJ, et al: Transvaginal ultrasonography and endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Maturitas 25:45-50, 1996
24. Neven P, Vergote I: Should tamoxifen users be screened for endometrial lesions? Lancet 351:155-156, 1998
25. Mourits MJE, De Vries EGE, Willemse PHB, et al: Tamoxifen treatment and gynecologic side effects: A review. Obstet Gynecol 97:855-866, 2001
26. Timmerman D, Deprest J, Bourne T, et al: A randomized trial on the use of ultrasonography or office hysteroscopy for endometrial assessment in postmenopausal patients with breast cancer who were treated with tamoxifen. Am J Obstet Gynecol 179:62-70, 1998